The Bill & Melinda Gates Foundation has provided a $2.9 million grant for the development of vaccines against tuberculosis, HIV, and malaria. The grant was issued to Aeras, a nonprofit biotech advancing TB vaccines for the world, the University of Oxford, and Okairos, a biopharmaceutical company specializing in T-cell vaccines. The three groups will work together to develop scalable methods to enable large-scale production of multiple novel chimpanzee adenovirus vector constructs.
The Interim CEO of Aeras, Tom Evans, said the “effort to improve optimization and scale-up under current good manufacturing practices could also potentially benefit our peers in HIV and malaria vaccine development.”
The University of Oxford is currently developing multiple vaccines, including vaccines against HIV, malaria, and TB in clinical trials in the UK and Africa. Aeras has focused primarily on tuberculosis vaccine research and development.
This construct will be Okairos’ proprietary technology platform that uses potent chimpanzee adenovirus vectors to stimulate robust T-cell and antibody responses against selected antigens.
Chimpanzee adenovirus-based vaccines have been shown to safely induce exceptionally potent cellular immunity in adults, children and infants, and are in clinical trials involving over 1,000 vaccinees in seven countries.
– Essee Oruma
Source: Bill & Melinda Gates Foundation